Corporate Banner
Satellite Banner
Technology Networks Header
Friday, November 28, 2014
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Gene Therapy Provides Safe, Long-Term Relief for Patients with Severe Hemophilia B
Gene therapy pioneered by St. Jude Children’s Research Hospital, University College London and the Royal Free Hospital provides men with hemophilia B reliable relief from the bleeding disorder.
Protein Predicts Response To New Immunotherapy Drug
Trial shows that response to treatment may be predicted by the presence of an immune-suppressing protein in non-cancerous immune cells.
Researchers Develop Efficient Method to Produce Nanoporous Metals
New technique to manufacture nanoporous metals is cheap and can be done over many scales.
Turkeys may be Lifesavers
Antibiotic to target staph infections, strep, comes from good bacteria in turkeys.
A Hybrid Vehicle That Delivers DNA
University at Buffalo researchers are developing new technology to improve DNA vaccines. The new transport system for DNA vaccines could help treat HIV, malaria, HPV and other major illnesses.
Big Data Set To Make A Big Difference In Childhood Cancer Treatment
UTS researchers are working with the Kids Research Institute to visualise large quantities of patient data to better diagnose and treat childhood cancer patients.
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
A Link between DNA Transcription and Disease-Causing Expansions Which Lead to Hereditary Disorders
A Tufts University study explores the relationship between transcription and the expansions of DNA repeats.
Did You Hear The One About The Two Businessmen On A Plane?
EquipNet’s vision ‘to revolutionize the way companies manage their surplus assets’ was first conceived at 30,000 feet somewhere between Chicago and Boston in 1999. Here we learn more about the company's first 15 years.
New Advance in Cryopreservation Could Change Management of World Blood Supplies
Engineers have identified a method to rapidly prepare frozen red blood cells for transfusions.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv